GrantZIANCI Division of Basic Sciences (intramural)
PCNA as an oncogenic drug target
- Activity
- ZIA
- Institute
- NCI Division of Basic Sciences (intramural)
- Fiscal years counted
- 2024
- Amount counted
- $200,189
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Abstract public domain (NIH RePORTER)
In this project we are using structure-based drug design to target proliferating cell nuclear antigen, PCNA, a protein that plays an essential role in DNA replication and repair. PCNA has been found to be a marker for poor prognosis of cancer patients in different cancers, such as pancreatic cancer and breast cancer. There are a few PCNA inhibitors already in clinical trials. We are structural biology techniques to determine the structure of PCNA and design novel inhibitors. We are also using a novel compound screening approach in collaboration with the Mackey lab (Virginia Tech), where we can test our compounds in a cellular environment which obtaining clear data of their efficacy in penetrating cells and inhibiting PCNA.